NCT01327651View on ClinicalTrials.gov

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

PHASE2CompletedINTERVENTIONAL

Enrollment

622

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

HIV Infections

Interventions

DRUG

Daily dosing

A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.

DRUG

Time-driven dosing

TDF/FTC twice weekly with a post-exposure dose

DRUG

Event-driven dosing

TDF/FTC as needed with a post exposure dose

Trial Locations (3)

7750

Emavundleni CRS, Cape Town

10027

Harlem Prevention Center CRS, New York

11000

Silom Community Clinic CRS, Nonthaburi

All Listed Sponsors

lead

HIV Prevention Trials Network

NETWORK

NCT01327651 - The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP) | Biotech Hunter | Biotech Hunter